Publications en collaboration avec des chercheurs de Klinikum der Universität München (1)

2016

  1. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1660-1668